Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Equivalent Impact of Elevated Lipoprotein(a) and Familial Hypercholesterolemia in Patients With Atherosclerotic Cardiovascular Disease
Berit Storgaard Hedegaard, Christian Sørensen Bork, Morten Kaltoft, et al.
Journal of the American College of Cardiology (2022) Vol. 80, Iss. 21, pp. 1998-2010
Open Access | Times Cited: 33

Showing 1-25 of 33 citing articles:

International Atherosclerosis Society guidance for implementing best practice in the care of familial hypercholesterolaemia
Gerald F. Watts, Samuel S. Gidding, Robert A. Hegele, et al.
Nature Reviews Cardiology (2023) Vol. 20, Iss. 12, pp. 845-869
Open Access | Times Cited: 128
Frequent questions and responses on the 2022 lipoprotein(a) consensus statement of the European Atherosclerosis Society
Florian Kronenberg, Samia Mora, Erik S.G. Stroes, et al.
Atherosclerosis (2023) Vol. 374, pp. 107-120
Open Access | Times Cited: 55
Lipoprotein(a) and cardiovascular disease
Børge G. Nordestgaard, Anne Langsted
The Lancet (2024)
Closed Access | Times Cited: 21
Lipoprotein Apheresis: Current Recommendations for Treating Familial Hypercholesterolemia and Elevated Lipoprotein(a)
Maya Safarova, Patrick M. Moriarty
Current Atherosclerosis Reports (2023) Vol. 25, Iss. 7, pp. 391-404
Closed Access | Times Cited: 23
Lipoprotein(a) and cardiovascular disease: sifting the evidence to guide future research
Pia R. Kamstrup, R. Dermot G. Neely, Steven E. Nissen, et al.
European Journal of Preventive Cardiology (2024) Vol. 31, Iss. 7, pp. 903-914
Open Access | Times Cited: 9
Novel Therapies for Lipoprotein(a): Update in Cardiovascular Risk Estimation and Treatment
Anders Berg Wulff, Børge G. Nordestgaard, Anne Langsted
Current Atherosclerosis Reports (2024) Vol. 26, Iss. 4, pp. 111-118
Closed Access | Times Cited: 9
Association of Lipoprotein (a) and Standard Modifiable Cardiovascular Risk Factors With Incident Myocardial Infarction: The Mass General Brigham Lp(a) Registry
Arthur Shiyovich, Adam N. Berman, Stephanie A. Besser, et al.
Journal of the American Heart Association (2024) Vol. 13, Iss. 10
Open Access | Times Cited: 5
Rethinking Cardiovascular Risk: The Emerging Role of Lipoprotein(a) Screening
Victoria Clair, Francis Zirille, Edward A. Gill
American Journal of Preventive Cardiology (2025) Vol. 21, pp. 100945-100945
Open Access
Living with Elevated Lipoprotein(a) Levels: The Experiences of Patients and Caregivers
Elisabeth Steinhagen‐Thiessen, Magdalena Daccord, Emma C Print, et al.
Patient Preference and Adherence (2025) Vol. Volume 19, pp. 395-405
Open Access
Updates in Small Interfering RNA for the Treatment of Dyslipidemias
Stefano Carugo, Cesare R. Sirtori, Guido Gelpi, et al.
Current Atherosclerosis Reports (2023) Vol. 25, Iss. 11, pp. 805-817
Open Access | Times Cited: 12
Leveraging drug-target Mendelian randomization for tailored lipoprotein-lipid lowering
Éloi Gagnon, Benoît J. Arsenault
Current Opinion in Lipidology (2025)
Closed Access
The need for national and international registries of patients with elevated lipoprotein(a)
Adam I. Kramer, Iulia Iatan, Liam R. Brunham
Current Opinion in Lipidology (2025)
Closed Access
Lipoprotein(a): cardiovascular risk and emerging therapies
Masashi Fujino, Stephen J. Nicholls
Expert Review of Cardiovascular Therapy (2023) Vol. 21, Iss. 4, pp. 259-268
Closed Access | Times Cited: 10
Therapy for Hyperlipidemia
Jennifer Wright, Savitha Subramanian
Medical Clinics of North America (2024) Vol. 108, Iss. 5, pp. 881-894
Closed Access | Times Cited: 3
Targeting PCSK9 as a key player in lipid metabolism: exploiting the therapeutic and biosensing potential of aptamers
Maryam Mahjoubin‐Tehran, Samaneh Rezaei, Raúl D. Santos, et al.
Lipids in Health and Disease (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 2
Eight reasons why lipoprotein(a) should be measured in everyone at least once in a lifetime
Benoît J. Arsenault, Pia R. Kamstrup
European Heart Journal (2024) Vol. 45, Iss. 30, pp. 2692-2694
Open Access | Times Cited: 2
The effect of adjusting LDL-cholesterol for Lp(a)-cholesterol on the diagnosis of familial hypercholesterolaemia
Darmiga Thayabaran, Anson P.T. Tsui, Stefan Ebmeier, et al.
Journal of clinical lipidology (2023) Vol. 17, Iss. 2, pp. 244-254
Open Access | Times Cited: 5
High Lipoprotein(a) May Explain One-Quarter of Clinical Familial Hypercholesterolemia Diagnoses in Danish Lipid Clinics
Berit Storgaard Hedegaard, Børge G. Nordestgaard, Helle Kanstrup, et al.
The Journal of Clinical Endocrinology & Metabolism (2023) Vol. 109, Iss. 3, pp. 659-667
Closed Access | Times Cited: 5
Measuring lipoprotein(a) for cardiovascular disease prevention – in whom and when?
P. E. Thomas, Signe Vedel‐Krogh, Børge G. Nordestgaard
Current Opinion in Cardiology (2023) Vol. 39, Iss. 1, pp. 39-48
Closed Access | Times Cited: 5
Predictors of cardiovascular risk in familial hypercholesterolemia
Manuel Romero, María Elena Mansilla-Rodríguez, Eva Nadiejda Gutiérrez-Cortizo
Current Opinion in Lipidology (2023) Vol. 34, Iss. 6, pp. 272-277
Closed Access | Times Cited: 4
Precise versus pragmatic - a perspective and evaluation of Lipoprotein(a) testing recommendations: A fellow's voice
Alexander C. Razavi
American Journal of Preventive Cardiology (2024) Vol. 17, pp. 100637-100637
Open Access | Times Cited: 1
Predictors of cardiovascular risk in familial hypercholesterolemia
Manuel Romero, María Elena Mansilla-Rodríguez
Current Opinion in Endocrinology Diabetes and Obesity (2024) Vol. 31, Iss. 5, pp. 191-196
Closed Access | Times Cited: 1
Lipoprotein(a) in children and adolescents with genetically confirmed familial hypercholesterolemia followed up at a specialized lipid clinic
Anja K. Johansen, Martin P. Bogsrud, Magne Thoresen, et al.
Atherosclerosis Plus (2024) Vol. 57, pp. 13-18
Open Access | Times Cited: 1
A machine learning algorithm for the identification elevated Lp(a) in patients with, or high-risk of having, coronary heart disease
Rosa Fernández Olmo, Gustavo M Cortez, Miriam Martín Toro, et al.
International Journal of Cardiology (2024) Vol. 418, pp. 132612-132612
Closed Access | Times Cited: 1
Lipoprotein(a) as underestimated cardiovascular risk factor in Russia. Time to introduce into clinical practice
O. Afanasieva, S. Pokrovsky
Russian Journal of Cardiology (2024) Vol. 29, Iss. 8, pp. 6035-6035
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top